0.9277
Schlusskurs vom Vortag:
$0.9323
Offen:
$0.93
24-Stunden-Volumen:
1.65M
Relative Volume:
0.43
Marktkapitalisierung:
$150.85M
Einnahmen:
$400.57M
Nettoeinkommen (Verlust:
$9.21M
KGV:
23.19
EPS:
0.04
Netto-Cashflow:
$146.36M
1W Leistung:
-4.41%
1M Leistung:
-30.77%
6M Leistung:
-79.34%
1J Leistung:
-88.58%
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Firmenname
Ironwood Pharmaceuticals Inc
Sektor
Telefon
617-621-7722
Adresse
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Vergleichen Sie IRWD mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
IRWD
Ironwood Pharmaceuticals Inc
|
0.9277 | 150.85M | 400.57M | 9.21M | 146.36M | 0.04 |
![]()
ZTS
Zoetis Inc
|
158.06 | 68.50B | 9.26B | 2.49B | 2.30B | 5.47 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
15.38 | 47.71B | 30.25B | 1.37B | 5.08B | 0.4257 |
![]()
HLN
Haleon Plc Adr
|
10.63 | 46.12B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.39 | 18.55B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
298.70 | 13.40B | 2.76B | 1.11B | 898.10M | 22.77 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-15 | Herabstufung | Jefferies | Buy → Hold |
2025-04-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2025-04-14 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
2024-09-09 | Eingeleitet | Leerink Partners | Market Perform |
2024-08-08 | Herabstufung | CapitalOne | Overweight → Equal Weight |
2024-01-17 | Eingeleitet | Craig Hallum | Buy |
2023-12-14 | Eingeleitet | Wells Fargo | Overweight |
2023-11-09 | Eingeleitet | Jefferies | Buy |
2023-09-28 | Eingeleitet | JMP Securities | Mkt Outperform |
2022-09-02 | Eingeleitet | CapitalOne | Overweight |
2022-04-22 | Eingeleitet | Piper Sandler | Overweight |
2020-09-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2020-06-17 | Eingeleitet | Northland Capital | Outperform |
2019-07-10 | Fortgesetzt | Credit Suisse | Neutral |
2019-03-27 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
2019-02-25 | Hochstufung | H.C. Wainwright | Sell → Neutral |
2019-01-24 | Hochstufung | JP Morgan | Underweight → Neutral |
2018-11-07 | Herabstufung | Credit Suisse | Outperform → Neutral |
2018-11-07 | Herabstufung | JP Morgan | Neutral → Underweight |
2018-07-23 | Eingeleitet | H.C. Wainwright | Sell |
2018-05-09 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
2018-01-05 | Herabstufung | BofA/Merrill | Buy → Underperform |
2017-12-06 | Herabstufung | Mizuho | Buy → Neutral |
2017-07-21 | Herabstufung | JP Morgan | Overweight → Neutral |
2017-05-03 | Eingeleitet | Wells Fargo | Outperform |
2017-04-07 | Bestätigt | Mizuho | Buy |
2017-02-22 | Bestätigt | Barclays | Equal Weight |
2016-11-04 | Bestätigt | Mizuho | Buy |
2016-10-24 | Bestätigt | Wedbush | Neutral |
2016-10-10 | Bestätigt | Mizuho | Buy |
2016-09-27 | Bestätigt | WallachBeth | Hold |
Alle ansehen
Ironwood Pharmaceuticals Inc Aktie (IRWD) Neueste Nachrichten
Analysts Estimate Ironwood Pharmaceuticals (IRWD) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Ironwood Pharmaceuticals to Participate in The Citizens Life Sci - GuruFocus
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference - Business Wire
Press Release Distribution & PR Platform - ACCESS Newswire
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. - GuruFocus
Ironwood Pharmaceuticals (IRWD) Boosts Earnings Outlook for 2025 - GuruFocus
Ironwood Pharmaceuticals (IRWD) Boosts FY25 EBITDA Forecast Amid Strong Demand | IRWD Stock News - GuruFocus
Ironwood Pharmaceuticals hikes adjusted EBITDA guidance to greater than $105M, shares rise - MSN
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance - ADVFN
Ironwood Pharmaceuticals Reiterates Full-Year 2025 Guidance and Raises Adjusted EBITDA - TradingView
Ironwood Pharmaceuticals to Present Real-World Data at Digestive - GuruFocus
Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support - itemonline.com
Ironwood looks for strategic options after regulatory hurdle for lead drug - MSN
Ironwood Pharmaceuticals to Explore Strategic Alternatives to Maximize Value for Stockholders - marketscreener.com
Why Ironwood Pharmaceuticals Inc. (IRWD) Went Down On Thursday? - MSN
Ironwood Shares Tank on Regulatory Update for Apraglutide - MSN
Ironwood Pharmaceuticals (IRWD) Faces Setback After FDA Request - GuruFocus
Ironwood Pharmaceuticals (IRWD) Faces Downgrade and Challenges A - GuruFocus
Ironwood Pharmaceuticals (IRWD) Faces Downgrade and Challenges Amid FDA Trial Delay | IRWD Stock News - GuruFocus
Ironwood downgraded at Jefferies on apraglutide-related challenges - MSN
Jefferies Downgrades Ironwood Pharmaceuticals (IRWD) - MSN
Wells Fargo Downgrades Ironwood Pharmaceuticals (IRWD) - MSN
Ironwood downgraded at Jefferies on apraglutide-related challenges (IRWD:NASDAQ) - Seeking Alpha
This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Wells Fargo Downgrades Ironwood Pharmaceuticals to Equalweight From Overweight, Adjusts Price Target to $1 From $7 - marketscreener.com
Jefferies Downgrades Ironwood Pharmaceuticals to Hold From Buy, Adjusts Price Target to $0.70 From $8 - marketscreener.com
Ironwood crashes down as FDA seeks new phase 3 trial - Pharmaphorum
Ironwood (IRWD) Shares Downgraded by Jefferies Following FDA Set - GuruFocus
Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide | IRWD Stock News - GuruFocus
Ironwood (IRWD) Plummets After Downgrade and FDA Trial Delay | I - GuruFocus
Ironwood To Consider All Options With Apraglutide Setback In SBS - insights.citeline.com
Ironwood's Strategy Shake-Up Raises Eyebrows As Shares Tumble - Finimize
Ironwood requires new trial for SBS drug approval By Investing.com - Investing.com South Africa
Top Midday Decliners - MarketScreener
Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug - Benzinga
Ironwood to considers merger opportunities after FDA setback - The Business Journals
Crude Oil Moves Lower; M&T Bank Earnings Miss Views - Benzinga
Ironwood (IRWD) Faces Financial Uncertainty as Price Target is S - GuruFocus
Ironwood (IRWD) Plummets After Downgrade and FDA Trial Delay | IRWD Stock News - GuruFocus
Ironwood (IRWD) Faces Financial Uncertainty as Price Target is Slashed | IRWD Stock News - GuruFocus
Ironwood: FDA nay on PK means another apraglutide study - BioWorld MedTech
Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide - BioSpace
Ironwood Pharma Shares Fall on Word of Confirmatory Phase 3 Apraglutide Trial - MarketWatch
Ironwood Pharmaceuticals (IRWD) Considers Strategic Options Afte - GuruFocus
Ironwood Pharmaceuticals stock tumbles after FDA requires additional trial By Investing.com - Investing.com South Africa
Ironwood Pharmaceuticals stock tumbles after FDA requires additional trial - Investing.com Australia
Nasdaq Surges 2%; Goldman Sachs Posts Upbeat Earnings - Benzinga
Ironwood Says FDA to Require Additional Phase 3 Trial for Apraglutide; to Explore Strategic Options - MarketScreener
Ironwood Pharma stock down on regulatory hurdle (IRWD:NASDAQ) - Seeking Alpha
Ironwood Pharma Provides Update On Apraglutide; Plans Strategic Alternatives - Nasdaq
Ironwood (IRWD) Plans New Phase 3 Trial for Apraglutide Followin - GuruFocus
Finanzdaten der Ironwood Pharmaceuticals Inc-Aktie (IRWD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ironwood Pharmaceuticals Inc-Aktie (IRWD) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Silver Ronald | Principal Accounting Officer |
Feb 10 '25 |
Sale |
1.76 |
12,048 |
21,204 |
279,655 |
Shetzline Michael | SVP, CMO, Head-Res&Drug |
Feb 10 '25 |
Sale |
1.76 |
41,269 |
72,633 |
554,007 |
John Minardo | Chief Legal Officer |
Feb 10 '25 |
Sale |
1.76 |
38,938 |
68,531 |
408,132 |
Martini Gregory S. | Chief Financial Officer |
Feb 10 '25 |
Sale |
1.76 |
12,052 |
21,212 |
183,810 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):